Positive Lexeo Therapeutics, Inc. interim data from SUNRISE-FA study highlights LX2006's potential for Friedreich's Ataxia.

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

“We are still a work in progress. We are not where we think we ... That was the plan from the get-go; we want to play one game at a time.” The 2025 BAL teams have been divided into three ...

The U.S. market showed signs of calming Tuesday as the Trump administration signaled progress on trade negotiations. "We were having a discussion last night about which countries to prioritize ...

Donald Trump has claimed “tremendous progress” in his trade war as he ... because her fiscal rules were written at a time that did not foresee the type of economic damage that will come ...

TIME met the males (Khaleesi was not present ... the first edited animals that have come from the labs, both represent progress. Still, scientists not affiliated with the company stress that ...

"They also discussed U.S. reciprocal tariffs on India and how to make progress toward a fair and balanced trade relationship," the State Department said in a statement. "Agreed on the importance ...

“Is it time to buy the dip? If stocks haven’t bottomed, we think they are close,” analysts at LPL Financial wrote in a commentary. They also said the market may be close to “a level at ...